Cargando…

Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma

Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kao, Chien-Hsiang, Liu, Chien-Ting, Lin, Hao, Huang, Yung-Cheng, Lan, Jui, Ou, Yu-Che, Fu, Hung-Chun, Wu, Chen-Hsuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797856/ https://www.ncbi.nlm.nih.gov/pubmed/36591227 http://dx.doi.org/10.3389/fimmu.2022.1079253

Ejemplares similares

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
por: Liu, Yung-Hao, et al.
Publicado: (2021)

Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)

Abscopal effect induced by modulated radiation therapy and pembrolizumab in a patient with pancreatic metastatic lung squamous cell carcinoma
por: Wang, Weiwei, et al.
Publicado: (2020)

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Cyriac, Sanju, et al.
Publicado: (2021)

Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
por: Chan, John K., et al.
Publicado: (2020)

Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab
por: Tsui, James M, et al.
Publicado: (2018)

Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab
por: Rittberg, Rebekah, et al.
Publicado: (2022)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
por: Porragas-Paseiro, Hector S., et al.
Publicado: (2023)

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
por: Song, Haa-Na, et al.
Publicado: (2018)

Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab
por: Mampuya, Wambaka Ange, et al.
Publicado: (2021)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
por: van der Woude, Lieke L, et al.
Publicado: (2022)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival
por: Nakamori, Keita, et al.
Publicado: (2022)

Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report
por: Nguyen, Olav Toai Duc, et al.
Publicado: (2020)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
por: Lam, Clarissa, et al.
Publicado: (2022)

Engineered nanomaterials trigger abscopal effect in immunotherapy of metastatic cancers
por: Xia, Yuanliang, et al.
Publicado: (2022)

Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
por: Cardona, Andrés F., et al.
Publicado: (2021)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Case Report: Prolonged remission of metastatic cisplatin-refractory nasopharyngeal carcinoma with Pembrolizumab
por: Wang, Wei Cen, et al.
Publicado: (2023)

PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
por: Sachdeva, Manavi, et al.
Publicado: (2021)

A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses
por: Chao, Joseph, et al.
Publicado: (2021)

Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study
por: Ollivier, Luc, et al.
Publicado: (2022)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Abscopal Effect after Palliative Radiation Therapy for Metastatic Adenocarcinoma of the Esophagus
por: Bruton Joe, Moss, et al.
Publicado: (2018)

Abscopal effect of radiation in metastatic esophageal carcinoma: fourth reported case
por: Biswas, Rituparna, et al.
Publicado: (2023)

Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis
por: Pei, Rui, et al.
Publicado: (2021)

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
por: Gu, Yangchun, et al.
Publicado: (2021)

Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report
por: Umihira, Shuntaro, et al.
Publicado: (2022)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review
por: Tan, Sirui, et al.
Publicado: (2022)

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab
por: Bloom, Brooke C., et al.
Publicado: (2019)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
por: Kadota, Naoki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m2f2etukcuq5o0c7tgqn6aot2l